<DOC>
	<DOCNO>NCT00935558</DOCNO>
	<brief_summary>The primary aim study investigate time progression breast cancer patient vaccinate autologous dendritic cell pulse peptide combination adjuvant aromatase inhibitor ( AI ) , Thymosin 1 alpha interleukin-2 . The secondary aim investigate whether measurable immune response induce , evaluate clinical effect ( objective response rate ) vaccination regime .</brief_summary>
	<brief_title>Dendritic Cell Based Therapy Breast Cancer Patients</brief_title>
	<detailed_description>Only patient tumor &gt; 5 % positive p53 IHC refer treatment . All patient receive standard dosage AI +/- p53-DC vaccination . Patients express HLA-A2 also receive DC vaccination . Patients express HLA-A2 receive AI regard control . The vaccination regime consist primary 10 intradermal injection 1-2 week interval ( q1w x 4 → q2w x 6 ) p53 peptide-pulsed dendritic cell , follow monthly injection progression ; proleukin Zadaxin use vaccine adjuvant . Defined procedure employ generation autologous dendritic cell clinical application classify laboratory . Unmobilized leukapheresis use isolation large-scale mononuclear cell , dendritic cell generate monocyte cytokine stimulation load p53 peptide . Frozen preparation dendritic cell prepare use automate cryopreservation.Each patient receive minimum 5x10^6 dendritic cell per treatment supplement interleukin-2 6 MIU/m² sc per vaccine 1.6 mg Thymosin 1 alpha sc x 2/week . Toxicity include autoimmunity evaluate use common Toxicity Criteria ( CTC ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Patients histological proven metastatic locally advanced ER+/PGR+ breast cancer progression receive 1. line endocrine therapy . Further inclusion criterion : p53+ tumour , PS≤1 , postmenopausal . Age &gt; 18 , PS ≤ 1 acceptable CBC blood chemistry result Patients history neoplastic disease le 5 year ago ( except treat carcinoma situ cervix basal/squamous carcinoma skin ) Patients metastatic disease central nervous system Patients significant illness include severe allergy , asthma , DM , angina pectoris congestive heart failure Patients acute chronic infection include HIV , hepatitis og TB Patients receive antineoplastic therapy include chemotherapy , radiation , immunotherapy agent , less 4 week begin trial Patients receive corticosteroid immunosuppressive agent Patients active autoimmune disease lupus erythematosus , rheumatoid arthritis thyroiditis Severe hypercalcemia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>dendritic cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>breast cancer</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>Zadaxin</keyword>
</DOC>